CG Oncology, Inc. financial data

Symbol
CGON on Nasdaq
Location
Irvine, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2692% % -26%
Debt-to-equity 4% % 24%
Return On Equity -22% % -14%
Return On Assets -21% % -35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80,666,179 shares 19%
Common Stock, Shares, Outstanding 78,277,452 shares 16%
Common Stock, Value, Issued $8,000 USD 14%
Weighted Average Number of Shares Outstanding, Basic 76,729,726 shares 14%
Weighted Average Number of Shares Outstanding, Diluted 76,729,726 shares 14%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $113,482,000 USD 58%
General and Administrative Expense $67,238,000 USD 169%
Operating Income (Loss) $180,123,000 USD -88%
Nonoperating Income (Expense) $28,639,000 USD 24%
Net Income (Loss) Attributable to Parent $151,484,000 USD -108%
Earnings Per Share, Basic -2 USD/shares 63%
Earnings Per Share, Diluted -2 USD/shares 63%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $45,145,000 USD 4%
Marketable Securities, Current $635,118,000 USD 28%
Inventory, Net $1,501,000 USD
Assets, Current $695,790,000 USD 26%
Property, Plant and Equipment, Net $15,329,000 USD 24232%
Operating Lease, Right-of-Use Asset $4,203,000 USD 1428%
Goodwill $12,805,000 USD
Other Assets, Noncurrent $114,000 USD 115%
Assets $729,913,000 USD 32%
Accounts Payable, Current $9,193,000 USD 126%
Liabilities, Current $30,528,000 USD 95%
Operating Lease, Liability, Noncurrent $3,329,000 USD 4589%
Other Liabilities, Noncurrent $3,804,000 USD
Liabilities $42,270,000 USD 169%
Retained Earnings (Accumulated Deficit) $337,667,000 USD -81%
Stockholders' Equity Attributable to Parent $687,643,000 USD 28%
Liabilities and Equity $729,913,000 USD 32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $29,277,000 USD -13%
Net Cash Provided by (Used in) Financing Activities $450,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $186,769,000 USD 39%
Common Stock, Shares Authorized 700,000,000 shares 0%
Common Stock, Shares, Issued 78,277,452 shares 16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $215,596,000 USD -412%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $45,145,000 USD 4%
Deferred Tax Assets, Valuation Allowance $56,402,000 USD 85%
Deferred Tax Assets, Gross $56,453,000 USD 85%
Operating Lease, Liability $4,241,000 USD 1333%
Depreciation $500,000 USD
Payments to Acquire Property, Plant, and Equipment $16,000 USD 33%
Lessee, Operating Lease, Liability, to be Paid $4,909,000 USD 1542%
Property, Plant and Equipment, Gross $15,952,000 USD
Operating Lease, Liability, Current $912,000 USD 305%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,137,000 USD 2087%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,162,000 USD 521%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 307%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $668,000 USD 22167%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,116,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $34,612,000 USD 92%
Unrecognized Tax Benefits $1,397,000 USD 40%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,039,000 USD
Operating Lease, Payments $443,000 USD 101%
Additional Paid in Capital $1,025,302,000 USD 42%
Depreciation, Depletion and Amortization $24,000 USD 500%
Deferred Tax Assets, Net of Valuation Allowance $56,402,000 USD 85%
Share-based Payment Arrangement, Expense $24,479,000 USD 240%